Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IMAC Holdings, Inc. stock logo
BACK
IMAC
$0.07
+13.3%
$0.05
$0.03
$2.10
$124K2.18676,049 shs1,756 shs
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
$0.00
$0.00
$0.00
$0.00
$5K0.9616,209 shs18,587 shs
OpGen, Inc. stock logo
OPGN
OpGen
$0.04
$3.99
$0.04
$5.25
$396K-1.668,849 shs1 shs
UPHL
UpHealth
$0.00
$0.00
$0.00
$0.44
$4K0.866,235 shs1,389 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IMAC Holdings, Inc. stock logo
BACK
IMAC
+13.33%+13.33%+36.00%+87.33%-96.26%
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00%0.00%0.00%-50.00%-98.33%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%+0.77%-99.17%-99.24%-98.68%
UPHL
UpHealth
0.00%0.00%0.00%0.00%-99.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/AN/AN/AN/AN/AN/AN/AN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
UPHL
UpHealth
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IMAC Holdings, Inc. stock logo
BACK
IMAC
0.00
N/AN/AN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
UPHL
UpHealth
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IMAC Holdings, Inc. stock logo
BACK
IMAC
$72.05K1.96N/AN/A($0.66) per share-0.10
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M0.15N/AN/A($11.55) per share0.00
UPHL
UpHealth
$130M0.00N/AN/A$3.10 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IMAC Holdings, Inc. stock logo
BACK
IMAC
-$9.42MN/A0.00N/AN/AN/A-325.44%8/4/2025 (Estimated)
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
-$39.76MN/A0.00N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A
UPHL
UpHealth
-$56.42M-$1.35N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/AN/AN/AN/AN/A
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
UPHL
UpHealth
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/A
0.08
0.08
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
UPHL
UpHealth
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
IMAC Holdings, Inc. stock logo
BACK
IMAC
5.84%
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
34.00%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
UPHL
UpHealth
56.10%

Insider Ownership

CompanyInsider Ownership
IMAC Holdings, Inc. stock logo
BACK
IMAC
12.26%
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
51.40%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
UPHL
UpHealth
34.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
IMAC Holdings, Inc. stock logo
BACK
IMAC
1802.07 million1.82 millionNot Optionable
Better Therapeutics, Inc. stock logo
BTTX
Better Therapeutics
4049.86 million24.23 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
UPHL
UpHealth
1,75018.93 million12.45 millionNo Data

Recent News About These Companies

Lemon Dump Cake Recipe
DJUSIV Dow Jones US Business Support Services Index
UpHealth Inc Ordinary Shares UPHL
UpHealth, Inc. (UPHL)

Media Sentiment Over Time

Top Headlines

View All Headlines
IMAC stock logo

IMAC NASDAQ:BACK

$0.07 +0.01 (+13.33%)
As of 08/1/2025 03:30 PM Eastern

IMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Franklin, Tennessee.

Better Therapeutics stock logo

Better Therapeutics NASDAQ:BTTX

$0.0001 0.00 (0.00%)
As of 08/1/2025 01:40 PM Eastern

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

OpGen stock logo

OpGen NASDAQ:OPGN

$0.04 0.00 (0.00%)
As of 07/31/2025

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

UpHealth NYSE:UPHL

$0.0002 0.00 (0.00%)
As of 07/31/2025 12:58 PM Eastern

UpHealth, Inc. provides behavioral health solutions through the utilization of evidence-based treatments and services in the Americas. The company offers mental health and substance use disorder treatment services directly to consumers. It also provides detoxification, residential, partial hospitalization program, intensive outpatient program, outpatient services, and non-clinical recovery residence and supporting housing services. UpHealth, Inc. is headquartered in Delray Beach, Florida.